Experts unpack BTK inhibitor use for relapsed primary CNS lymphoma, sharing Japan and Taiwan real‑world data, trials, and tiorotinib insights.
Motoo Nagane, MD, PhD
Advertisement
Articles by Motoo Nagane, MD, PhD
Experts debate BTK inhibitors for primary CNS lymphoma, sharing trial and real-world insights on tirabrutinib and options for relapsed disease.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Ropeginterferon Alfa-2b for Essential Thrombocythemia
2
FDA Approves Rusfertide for Polycythemia Vera
3
DESTINY-Breast05 Safety Analysis Clarifies ILD and Radiation Risks With T-DXd in HER2+ Breast Cancer
4
The OncFive: Top Oncology Articles for the Week of 8/23
5